

BEST AVAILABLE COPY



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : C12N 7/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 00/29557</p> <p>(43) International Publication Date: 25 May 2000 (25.05.00)</p>		
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(21) International Application Number: PCT/US99/24017</p> <p>(22) International Filing Date: 12 November 1999 (12.11.99)</p> <p>(30) Priority Data: 60/108,168 13 November 1998 (13.11.98) US</p> <p>(71) Applicant (for all designated States except US): CELL GENESYS, INC. [US/US]; 342 Lakeside Drive, Foster City, CA 94404 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): BUKOVSKY, Anatoly [RU/US]; Cell Genesys, Inc., 342 Lakeside Drive, Foster City, CA 94404 (US). NALDINI, Luigi [IT/US]; Cell Genesys, Inc., 342 Lakeside Drive, Foster City, CA 94404 (US).</p> <p>(74) Agents: NAKAMURA, Dean, H. et al.; Sughrue, Mion, Zinn, MacPeak & Seas, PLLC, Suite 800, 2100 Pennsylvania Avenue, N.W., Washington, DC 20037-3202 (US).</p> </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p> </td> </tr> </table>			<p>(21) International Application Number: PCT/US99/24017</p> <p>(22) International Filing Date: 12 November 1999 (12.11.99)</p> <p>(30) Priority Data: 60/108,168 13 November 1998 (13.11.98) US</p> <p>(71) Applicant (for all designated States except US): CELL GENESYS, INC. [US/US]; 342 Lakeside Drive, Foster City, CA 94404 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): BUKOVSKY, Anatoly [RU/US]; Cell Genesys, Inc., 342 Lakeside Drive, Foster City, CA 94404 (US). NALDINI, Luigi [IT/US]; Cell Genesys, Inc., 342 Lakeside Drive, Foster City, CA 94404 (US).</p> <p>(74) Agents: NAKAMURA, Dean, H. et al.; Sughrue, Mion, Zinn, MacPeak & Seas, PLLC, Suite 800, 2100 Pennsylvania Avenue, N.W., Washington, DC 20037-3202 (US).</p>	<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>
<p>(21) International Application Number: PCT/US99/24017</p> <p>(22) International Filing Date: 12 November 1999 (12.11.99)</p> <p>(30) Priority Data: 60/108,168 13 November 1998 (13.11.98) US</p> <p>(71) Applicant (for all designated States except US): CELL GENESYS, INC. [US/US]; 342 Lakeside Drive, Foster City, CA 94404 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): BUKOVSKY, Anatoly [RU/US]; Cell Genesys, Inc., 342 Lakeside Drive, Foster City, CA 94404 (US). NALDINI, Luigi [IT/US]; Cell Genesys, Inc., 342 Lakeside Drive, Foster City, CA 94404 (US).</p> <p>(74) Agents: NAKAMURA, Dean, H. et al.; Sughrue, Mion, Zinn, MacPeak & Seas, PLLC, Suite 800, 2100 Pennsylvania Avenue, N.W., Washington, DC 20037-3202 (US).</p>	<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>			
<p>(54) Title: A SENSITIVE SCREENING SYSTEM FOR ENVELOPE-DEFECTIVE RECOMBINANT VIRUS</p> <p>(57) Abstract</p> <p style="margin-left: 40px;">An indicator cell line which transcomplements envelope defective recombinant virus can be used to amplify that virus.</p>				

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

A Sensitive Screening System For Envelope-Defective Recombinant Virus

FIELD OF INVENTION

A sensitive screening system identifies envelope-defective recombinant viruses originating during production of lentiviral or retroviral vectors.

BACKGROUND OF THE INVENTION

Generally, recombinant viruses are replication-defective. However, such
5 recombinant viruses still may be harmful to vector production in several ways. First, recombinant viruses may be propagated in vector producer cells. Second, recombinant viruses can interfere with the transduction of the vector by competing during encapsidation of the viral particles. Moreover, recombinant viruses may be harmful to a vector recipient due to the transfer of vector
10 packaging functions. That may cause toxicity or an immune reaction in the transduced cells and host. There also may be an increase in the risk of additional recombination events which eventually could lead to generation of replication-competent retrovirus.

Such recombinant viruses may originate from the recombination of two
15 or more of the constructs used to produce the vector, or from one such construct and endogenous retroviral sequences expressed in vector producer or target cells. Recombinants generally contain viral cis-acting sequences required for encapsidation and transfer to the target cells. Recombinants also generally contain the gag/pol gene sequences of a retrovirus or lentivirus.

20 The extent to which defective recombinants, such as envelope defective recombinants, contaminate batches of vector produced for clinical use or influence the performance of a vector producer system, is often unknown. The risk of defective versus replication competent recombinants occurring is

increased with the new split-genome packaging cell lines for retroviral vectors and with the use of vector pseudotyping due to the lack of any overlap between the constructs encoding the envelope and the gag/pol genes. Although that implies a lower risk of replication-competent recombinants occurring, the
5 recombination between the gag/pol construct and the transfer vector carrying the foreign gene of interest may still occur and generate envelope-defective recombinants that go unnoticed in conventional screening.

Defective recombinants contaminating vector lots used in clinical trials also may be responsible for false positive results in certain assays used to
10 monitor replication-competent recombinants in the recipients.

Sensitive detection and early elimination of defective recombinants thus is crucial to validate and to maintain the performance of a vector producer system, as well as to prove the purity and safety of a vector batch. However, as defective recombinants are replication-defective as well, routine assays used to
15 monitor retroviral recombinants that are based on amplification through replication in the indicator cell line(s) cannot detect the defective recombinants.

SUMMARY OF THE INVENTION

The invention describes an amplification method which detects replication-defective recombinants that is based on transcomplementation in an
20 indicator cell line which provides the missing packaging functions, for example, an envelope gene to detect envelope-defective recombinants. An important feature of the complementing envelope is little if no interference with superinfection of the indicator cells thereby allowing under certain circumstances amplification by pseudoreplication of the recombinant in a
25 homogenous culture.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts how an envelope-defective recombinant can be generated from a packaging plasmid and a transfer vector carrying HIV sequences. The upper diagram depicts the wild-type HIV-1 genome. In the diagrams, LTR is a long terminal repeat; SD is a splice donor site; GAG is the group antigen coding sequence; PRO is the protease coding sequence; POL is the polymerase coding sequence; VIF and NEF are accessory genes; CMV is the cytomegalovirus enhancer/promoter; poly A is a polyadenylation site; the delta ENV designation indicated deletion of the envelope coding sequence; SA is a splice acceptor site; prom is a promoter; Transgene is a foreign gene of interest; ψ is an encapsidation signal sequence; TAT and REV are regulatory genes; and RRE is Rev Responsive Element. The solid blocks indicate the HIV open reading frames or functional genes in the three reading frames.

Figure 2 depicts the results of assays aimed at determining the sensitivity of the method of interest.

Figure 3 depicts the results of viral amplification in the absence or presence of the VSV G envelope.

DETAILED DESCRIPTION OF THE INVENTION

The detection of replication defective retroviral recombinants, particularly of lentivirus-based vectors, rests with providing in trans a complementing function for that suspected of being defective in the recombinants. For example, if detection of envelope-defective recombinants is desired, a means for providing envelope protein is utilized. That can be accomplished by developing transcomplementing cell lines which express one or more components needed for producing virus particles, such as an envelope protein.

An indicator cell line expressing a transcomplementing protein, such as, envelope protein, tat protein, rev protein or a combination thereof may be constructed and used as a screening agent in the instant invention.

Preferably the indicator cell lines are stable, transformed cells that
5 express the one or more transcomplementing factors. Generally a stable, transformed cell in one wherein the transgene encoding the desirable factor is integrated into the host genome. That can be accomplished, for example, by transfection or by using a vector known to integrate into a host genome, such as, a retroviral vector, a transposon-based vector or an adeno-associated viral vector
10 to carry the transgene.

Moreover, because a foreign gene product, such as an envelope protein, may be toxic to the host cell, it is desirable to regulate the expression of the transgene. For example, an inducible promoter may be used to control the expression of the transgene. Such inducible promoters are known in the art.

15 Otherwise, the making and maintenance of the transformed cell as well as the vectors of interest are as known in the art using materials readily available to the artisan. Any of a variety of host cells can be used. Moreover, the vectors and transgenes are known and the artisan can rely on known methods to construct a vector of interest.

20 Essentially, any known vector carrying a transcomplementing gene of interest and any suitable host cell can be used. Known inducible regulation systems can be used to regulate the expression of the transcomplementing gene. Also, any known method for detecting virus or expression of a gene product originating for the defective recombinant can be used, such as an immunoassay
25 for a gag protein.

The 293G cell line which expresses the envelope protein G of vesicular stomatitis virus (VSV) (Ory et al., Proc. Natl. Acad. Sci. 93:11400-11406, 1996) can be used to detect envelope-defective viruses wherein the entry thereof

in target cells can be mediated by said protein G. The G protein is of interest because that envelope glycoprotein has been found to complement a wide range of viruses. Expression of the VSV G protein in 293G is controlled in a tetracycline regulated manner.

5 The VSV G cell line can be used, for example, to amplify minimal amounts of envelope-defective recombinant viruses that can nevertheless express and transfer the gag/pol genes of HIV. With that tetracycline regulated system, the cells are maintained in the presence of tetracycline which suppresses the expression of VSV G. Removal of tetracycline from the culture medium
10 maintaining 293G cells results in induction of VSV G protein expression on the surface of the indicator cells thereby allowing for efficient pseudotyping and/or entry of the released viral particles. The particles in turn are capable of superinfecting the indicator cells which leads to amplification of the input viral recombinant.

15 The VSV G envelope is particularly useful by endowing the viral particles with a very high infectivity thereby enhancing the sensitivity and robustness of the assay.

Amplification of virus not only by viruses carrying the envelope glycoprotein but also by viruses which lack or do not express an envelope
20 glycoprotein has been observed. Thus, in the case of the VSV G protein, the expression of G protein at the surface of target cells is sufficient to mediate productive infection independent of expression within the viral membrane.

In view thereof, the instant invention relates to a method wherein screening of vector recipients following therapy can be accommodated. The
25 method also can be used to amplify other enveloped viruses for which natural cellular receptors have yet to be identified.

The instant assay will find use, for example, in the production of efficient and safe HIV-based lentiviral vectors. The growth of the recombinant particles

can be detected by immunoenzymatic assays detecting, for example, the HIV p24 gag antigen, or by RNA-PCR assays for detecting the HIV gag gene. Then, the presence of defective recombinants can be monitored by the use of the instant indicator cells.

5 The instant method also can be used to identify partial recombinant viruses that express and transfer the gag/pol genes of other retroviruses, for example, the lentivirus, such as, the various SIV's, FIV, HIV-2, visna-maedi virus, caprine arthritis-encephalitis virus, BIV and equine infectious anemia virus, and other retrovirus, such as, spumavirus, murine leukemia and sarcoma
10 viruses, other mammalian C-type viruses, such as FeLV and simian sarcoma virus, HERV's, B-type virus, such as mouse mammary tumor virus, D-type virus, HTLV's, bovine leukemia virus and avian leukosis-sarcoma viruses, such as Rous sarcoma virus and avian myeloblastosis virus. The detection system of the recombinant particle would be adjusted to the genes of the selected virus.

15 In another embodiment of the invention, the indicator cell line transcomplements one or both of the essential regulatory genes of lentivirus, tat and rev, in addition to the envelope gene. Such a system is useful to identify partial recombinants that contain the gag/pol genes of a lentivirus but do not express those genes efficiently, because for example, the regulatory genes
20 required for efficient expression of the gag/pol genes are lacking or are defective. Suitable assays would be those detecting expression of gag or pol.

 The amplification provided by the instant method in the case of detecting envelope-defective recombinants arises from the significantly more efficient viral entry mediated by the complementing envelope proteins as compared to
25 the homologous or parental gene product. Thus, another use of the instant method is a fast selection of viral gene variants of a desired phenotype, such as drug-resistance or growth advantage. The selection could be performed without

the need of actually producing an infectious viral construct as a complementing envelope protein can be produced by a cell, such as an indicator cell of interest.

The invention now will be exemplified in the following non-limiting examples.

5

EXAMPLES

For validation of the detection system, an envelope-defective recombinant was constructed by molecular cloning using known techniques. A VSV G protein expressing construct, pMD.G, which does not contain HIV sequences, was used (Naldini et al., Science 272:263-267, 1996a). Viral particles were generated by co-transfecting an envelope-defective recombinant construct and the VSV.G expressing construct into 293T cells (Naldini et al., 1996a, supra; Proc. Natl. Acad. Sci. 93:11382-11388, 1996b). The recombinant construct was an HIV-based vector containing all but envelope sequences.

Control virus was produced by means of transient transfection of the envelope-defective recombinant plasmid R8.7 delE and the VSV.G expressor plasmid pMD G (Naldini et al., 1996a, supra) into 293T cells. The R8.7 plasmid was constructed by cloning the BclI-XhoI fragment of plasmid pCMVDR8.74 (Dull et al., J. Virol. 72:8463-8471, 1998), which contains the HIV gag, pol, tat and rev genes but no accessory genes, into R8 (Gallay et al., Cell 83:569-576, 1995).

Cells were seeded in 10 cm dishes 24 hours before infection and washed 2 hours before transfection. Culture medium (IMDM, 10% FCS) was replaced at 14 hours and transfectant-conditioned medium was collected at 36 hours post transfection. The conditioned medium was cleared by low-speed centrifugation (1500g) and passed through 0.45 μ m filters. The amount of viral particles in the medium was measured by immunocapture assay for the HIV-1 p24 gag antigen (DuPont).

Titration of the viral particles on the VSV.G indicator cells by limiting dilution permitted an estimate of the sensitivity of the assay and provided a means to determine the amount of envelope-defective recombinants in vector preparations.

5 Indicator 293G cells (Ory et al., supra) and control 293-cells were seeded in 6-well plates at approximately 30% confluence 24 hours before infection. Immediately before infection, calls were washed with fresh medium. Control virus was diluted serially 10-fold in the medium without tetracycline and 1 ml of each dilution was added to each well. Cultured medium from infected cells
10 were replaced regularly and amplification of recombinants was monitored by measuring p24 antigens in the supernatant. Infected cells were split 1/5 after confluence was reached.

As provided in Figure 2, the system is capable of detecting an inoculum of viral particles encapsidating an envelope-defective construct at a level of less
15 than 20 fg p24 equivalent (lowest dilution used) in a 15 day incubation period. A gradual increase in p24 antigen concentration was observed in the culture supernatant on the indicated day after infection. No amplification of the recombinant was seen when 293 cells lacking the VSV envelope where infected with the same amount of viral particles.

20 The data of Figure 3 demonstrate the ability of the 293G cell to support virus amplification after initial infection by virus lacking envelope glycoprotein. Virions were produced by transient co-transfection of a plasmid encoding the HIV derivative containing deletion of the env gene and of either carrier DNA or the pMD.G plasmid encoding VSV G. Virions were normalized for p24
25 content, serially diluted (20, 0.5 and 0.125 ng/ml) and incubated with either induced 293/G cells or control 293 cells. As the expression of G in the 293G/ cell line is regulated by tetracycline, the cells were maintained in the absence of tetracycline 24 hours prior to infection.

During a two week period, supernatants of infected cells were monitored for p24 content as a measure of viral amplification. The data in Figure 3 are the results observed at the end of a two week period.

No p24 was detected in the supernatant of 293 cells incubated with
5 envelope-defective virions.

As expected, 293 cells infected with VSV G pseudotyped viruses produced low levels of p24 which was proportional to the input amount of virus and was not amplified throughout the incubation period. On the other hand, 293G cells generated increasing amounts of p24 with identical kinetics whether
10 pseudotyped or envelope defective virus was used for the initial infection.

We claim:

1. A method of amplifying an envelope-defective retrovirus by exposing said retrovirus to a cell comprising a virus envelope gene, wherein virus envelope encoded by said gene complements said retrovirus.
2. The method of claim 1, wherein said virus envelope is expressed at the surface of a virus particle produced by said cell.
3. The method of claim 1, wherein said virus envelope is expressed by said cell.




Figure 1




Figure 2. Amplification of partial recombinants lacking the Env gene.




Figure 3 Efficient Amplification of virions lacking Env glycoprotein

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/24017

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 7/00

US CL : 435/235.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/235.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,503,974 A (GRUBER ET AL) 02 April 1996 (02/04/96), see entire document, especially columns 4 and 6.	1-3
Y	US 5,591,579 A (OLIVO ET AL) 07 January 1997 (07/01/97), see entire document.	1-3
Y	US 5,614,404 A (MAZZARA ETAL) 25 March 1997 (25/03/97), see entire document.	1-3
Y	US 5,583,022 A (HEIDMANN ET AL) 10 December 1996 (10/12/96), see entire document.	1-3

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* "A"	Special categories of cited documents document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier document published on or after the international filing date	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claims; or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	
"P"	document published prior to the international filing date but later than the priority date claimed	"N" document member of the same patent family

Date of the actual completion of the international search

08 FEBRUARY 2000

Date of mailing of the international search report

23 FEB 2000

Name and mailing address of the ISA-US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ROBERT A. ZEMAN

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/24017

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

WEST, Medline, CAPlus, Biosis.

search terms: defective, retrovirus, amplification, detection, cell, indicator, envelope, env

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.